



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

Gap Junction Protein

Gap junction (GJ) channels span the plasma membranes of adjacent cells and are formed by the docking of two hemichannels (connexons) oligomerized from connexin (Cx) proteins, which consist of 21 distinct isoforms. GJs provide a direct pathway for cell-to-cell electrical signaling and metabolic communication, allowing the passage of small ions, amino acids, metabolites, tetraethylammonium and signaling molecules such as cAMP, IP₃, siRNA and small peptide.


Gap junction channels provide the basis for intercellular communication in the cardiovascular system for maintenance of the normal cardiac rhythm, regulation of vascular tone and endothelial function as well as metabolic interchange between the cells. In the heart, GJs mediate electrical coupling between cardiac myocytes, forming the cell-to-cell pathways for orderly spread of the wave of electrical excitation responsible for synchronous contraction. Gap junctions also play an important role in the control of bladder contractile response and in the regulation of various immune inflammatory processes.

Gap Junction Protein Inhibitors & Modulators

AT-1002

Cat. No.: HY-114426

AT-1002, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

AT-1002 TFA

Cat. No.: HY-114426A

AT-1002 TFA, a 6-mer synthetic peptide, is a tight junction regulator and absorption enhancer.




Purity: 99.72%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

Carbenoxolone disodium

Cat. No.: HY-B1367

Carbenoxolone disodium is the active metabolite of Glycyrrhizic acid (HY-N0184) and the inhibitor of human 11 β -HSD and bacterial 3 α , 20 β -HSD. Carbenoxolone disodium is an uncoupling agent for gap junctions and a potent inhibitor of Vaccinia virus replication.




Purity: 99.88%
Clinical Data: Launched
Size: 10 mM × 1 mL, 25 mg, 50 mg, 100 mg

Danegaptide

(GAP-134; ZP 1609)

Cat. No.: HY-10913

Danegaptide (GAP-134) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.




Purity: >98%
Clinical Data: Phase 2
Size: 1 mg, 5 mg

Danegaptide Hydrochloride

(GAP-134 Hydrochloride; ZP 1609 Hydrochloride)

Cat. No.: HY-10913A

Danegaptide Hydrochloride (GAP-134 Hydrochloride) is a potent, selective and orally active gap-junction modifier with an antiarrhythmic effect.



Purity: 99.75%
Clinical Data: Phase 2
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Gap 26

Cat. No.: HY-P1082

Gap 26 is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

VCYDKSFPISHVR

Purity: 99.64%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gap 26 TFA

Cat. No.: HY-P1082A

Gap 26 TFA is a connexin mimetic peptide, composed of residue numbers 63-75 of the first extracellular loop of connexin 43 (gap junction blocker), containing the SHVR amino acid motif.

VCYDKSFPISHVR (TFA Salt)

Purity: 99.03%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

Gap 27

Cat. No.: HY-P0139

Gap 27, a synthetic connexin43 mimetic peptide, is a gap junction inhibitor. Gap 27 possesses conserved sequence homology to a portion of the second extracellular loop leading into the fourth transmembrane connexin segment.


SRPTEKTIFII

Purity: 98.07%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

Gap19

Cat. No.: HY-P1136

Gap19, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg








Gap19 TFA

Cat. No.: HY-P1136A

Gap19 TFA, a peptide derived from nine amino acids of the Cx43 cytoplasmic loop (CL), is a potent and selective connexin 43 (Cx43) hemichannel blocker. Gap19 TFA inhibits hemichannels caused by preventing intramolecular interactions of the C-terminus (CT) with the CL.



Purity: 95.11%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg, 10 mg

<p>Larazotide acetate</p> <p style="text-align: right;">Cat. No.: HY-106268A</p> <p>Larazotide acetate is a synthetic peptide. Larazotide acetate acts as a tight junction regulator and reverses leaky junctions to their normally closed state.</p>  <p>Purity: 99.68% Clinical Data: Phase 3 Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg</p>	<p>Meclofenamic acid (Meclofenamate)</p> <p style="text-align: right;">Cat. No.: HY-117275</p> <p>Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor. Meclofenamic Acid competes with FTO binding for the m(6)A-containing nucleic acid.</p>  <p>Purity: >98% Clinical Data: Launched Size: 1 mg, 5 mg</p>
<p>Meclofenamic acid sodium (Meclofenamate sodium)</p> <p style="text-align: right;">Cat. No.: HY-B1320</p> <p>Meclofenamic acid (Meclofenamate) sodium is a nonsteroidal anti-inflammatory drug (NSAID) approved for use in arthritis (osteo and rheumatoid), analgesia (mild to moderate pain), dysmenorrhea, and heavy menstrual blood loss (menorrhagia).</p>  <p>Purity: 99.86% Clinical Data: Launched Size: 10 mM × 1 mL, 50 mg, 100 mg, 200 mg</p>	<p>Meclofenamic acid-d4 (Meclofenamate-d4)</p> <p style="text-align: right;">Cat. No.: HY-117275S</p> <p>Meclofenamic acid-d4 (Meclofenamate-d4) is the deuterium labeled Meclofenamic acid. Meclofenamic Acid (Meclofenamate), a non-steroidal, anti-inflammatory agent, is a highly selective fat mass and obesity-associated (FTO) enzyme inhibitor.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 10 mg</p>
<p>Peptide5</p> <p style="text-align: right;">Cat. No.: HY-P2275</p> <p>Peptide5, a connexin 43 mimetic peptide, reduce animals swelling, astrogliosis, and neuronal cell death after spinal cord injury.</p>  <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>Rotigaptide (ZP123)</p> <p style="text-align: right;">Cat. No.: HY-106225</p> <p>Rotigaptide (ZP123) is a novel and specific modulator of connexin 43 (Cx43). Rotigaptide prevents the uncoupling of Cx43-mediated gap junction communication and normalizes cell-to-cell communication during acute metabolic stress.</p>  <p>Purity: 99.63% Clinical Data: No Development Reported Size: 10 mM × 1 mL, 1 mg, 5 mg</p>
<p>TAT-Gap19</p> <p style="text-align: right;">Cat. No.: HY-P1136B</p> <p>TAT-Gap19, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 does not inhibit the corresponding Cx43 GJCs. TAT-Gap19 traverses the blood-brain barrier and alleviate liver fibrosis in mice.</p> <p style="text-align: center;">YGRKKRRQRRRKQIEIKKFK</p> <p>Purity: >98% Clinical Data: No Development Reported Size: 1 mg, 5 mg</p>	<p>TAT-Gap19 TFA</p> <p style="text-align: right;">Cat. No.: HY-P1136C</p> <p>TAT-Gap19 TFA, a Cx mimetic peptide, is a specific connexin43 hemichannel (Cx43 HC) inhibitor. TAT-Gap19 TFA does not inhibit the corresponding Cx43 GJCs. TAT-Gap19 TFA traverses the blood-brain barrier and alleviate liver fibrosis in mice.</p> <p style="text-align: center;">YGRKKRRQRRRKQIEIKKFK (TFA salt)</p> <p>Purity: 98.36% Clinical Data: No Development Reported Size: 5 mg, 10 mg</p>
<p>Tonabersat (SB-220453)</p> <p style="text-align: right;">Cat. No.: HY-15204</p> <p>Tonabersat (SB-220453) is a gap-junction modulator. Tonabersat prevents inflammatory damage in the central nervous system.</p>  <p>Purity: 98.36% Clinical Data: Phase 2 Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg</p>	